Integrative neuro-oncology for brain tumor patients

The University of Cincinnati's Soma Sengupta, MD, PhD, published an article in the Journal of Neuro-Oncology April 25 discussing her journey and approach to practicing integrative neuro-oncology.

Sengupta, associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist, funded by the Harold C. Schott Endowed Chair in Molecular Therapeutics (Neurosurgery) and the Pam and Tom Mischell Funds, said she personally experienced friends and family members looking for something beyond traditional treatment, palliative care and hospice.

"I became interested in integrative medicine when I realized there needed to be equipoise between "active treatment" and strategies to improve the quality of life for patients that could integrate a patient’s belief systems," she writes in the article.

Sengupta was a fellow at the Andrew Weil Integrative Medicine Center at the University of Arizona for two years, learning more about how integrative medicine can improve patient and caregiver care.

"We need to find innovative ways of integrating care for our neuro-oncology and oncology patients to improve their quality of life," Sengupta said. "Integrative medicine fellowships are intense and take several years, but arm the provider with a holistic way of thinking about medicine.

"The quality of life for each patient and their family member is as important as the treatment," Sengupta continued. "We look at ways to improve the providers well-being and their needs, and something similar needs to be done for our patients and their caregivers.

Sengupta S.
Integrative neuro-oncology for brain tumor patients.
J Neurooncol, 2023. doi: 10.1007/s11060-023-04309-3

Most Popular Now

Bayer Pharmaceuticals accelerates innovations for …

At its annual Pharma Media Day 2023, Bayer presented the latest progress in the ongoing transformation of its pharmaceutical business focusing on accelerating innovativ...

Novo Nordisk Foundation to support crucial educati…

The global shortage of qualified health professionals is an increasing challenge. According to the WHO, an additional 10 million health professionals will be needed by 20...

FDA accepts Pfizer's Supplemental New Drug Applica…

Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (e...

Candidate found to inhibit malignant melanoma grow…

Malignant melanoma is a relatively aggressive type of skin cancer. When detected early, it is usually treatable by surgical resection only, but metastases develop often s...

AI predicts enzyme function better than leading to…

A new artificial intelligence tool can predict the functions of enzymes based on their amino acid sequences, even when the enzymes are unstudied or poorly understood. The...

Tumor avatars to fight colorectal cancer

How to determine the most effective treatment for colon cancer? The response to chemotherapy varies greatly from one patient to another. A team from the UNIGE has develop...

CycPeptMPDB: A database aimed at promoting drug de…

CycPeptMPDB, a novel database - created by Tokyo Tech researchers - focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs bas...

How cancer evades immune system detection and spre…

A research team led by the National Cancer Centre Singapore (NCCS) with members from Duke-NUS Medical School, KK Women and Children’s Hospital, A*STAR's Singapore Immun...

Update to contractual arrangements between AstraZe…

AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commerciali...

New therapy harnesses patients' blood cells to fig…

Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patien...

Researchers leverage cell self-destruction to trea…

Glioblastoma is the most common type of brain tumor in adults. The disease is 100% fatal and there are no cures, making it the most aggressive type of cancer. Such a poor...

Anti-obesity medications could be sold for lower p…

New research shows that several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high...